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Abstract 
Animal models are essential research tools in modern biomedical research, but there are concerns 
about their lack of reproducibility and the failure of animal data to translate into advances in 
human medical therapy. A major factor in improving experimental reproducibility is thorough 
communication of research methodologies. The recently published ARRIVE guidelines outline basic 
information that should be provided when reporting animal studies. This paper builds on ARRIVE 
by providing the minimum information needed in reports to allow proper assessment of pathology 
data gathered from animal tissues. This guidance covers aspects of experimental design, technical 
procedures, data gathering, analysis and presentation that are potential sources of variation when 
creating morphological, immunohistochemical (IHC) or in situ hybridisation (ISH) datasets. This 
reporting framework will maximise the likelihood that pathology data derived from animal 
experiments can be reproduced by ensuring that sufficient information is available to allow for 
replication of the methods and facilitate inter-study comparison by identifying potential 
interpretative confounders. 
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Introduction 
Animal models are integral to understanding the pathogenesis and therapy of human disease 
[1,2,3]. However, the lack of reproducibility of preclinical animal studies has become an increasing 
cause for concern [4,5] due to an inability to replicate drug target discovery studies [6,7] and the 
divergent results obtained with widely accepted animal models of human disease [8’9].  
Many factors cause lack of robustness in the animal data. Some are inevitable, such as interspecies 
biological differences [10,11,12]. Many others are avoidable, including poor study design; 
inappropriate data analysis; peer review by individuals who have insufficient expertise in the 
species, model system or methods applied; failure to follow existing guidelines and career 
pressure to publish fast and often [5]. A lack of transparency in reporting, presenting as either 
incomplete disclosure of methods (sometimes due to journal word count restrictions) and/or a 
reluctance to report negative results often exacerbate these avoidable factors.  
Pathology data are a crucial endpoint in animal studies, the importance of which is often 
overlooked by research teams [13]. Morphological data can often explain other phenotypic data 
and are highly translatable, allowing direct comparison of pathological processes and/or 
histologically identifiable changes in animals with the human disease that is being modelled.  The 
reporting of pathology data is often limited to a figure (often restricted in size by journal formats 
so that diagnostic features are not, or only poorly, visible) and a brief description in the text 
(sometimes found only in the figure legend or the supplementary data section). Specific technical 
information is often not included or is incomplete in published reports, perhaps in part because 
many non-pathologists consider that basic pathology techniques are completely standardised in 
comparison with modern molecular, biochemical, genetic and “omics” platforms, or are arcane. In 
reality, many variables can affect the outcome of even “routine” pathology techniques, and failure 
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to define and account for these factors in a publication makes it impossible to fully review or 
critically evaluate the results.  
Improving reproducibility of animal models will require all aspects of studies to be transparent and 
open to scrutiny by journals, peer reviewers and readers. Guidelines are available and are being 
adopted to a variable degree by journals [14] covering general aspects of experimental design in 
animal studies (Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines, [15,16,17]; 
technique-specific details (MIQE guidelines for rtPCR, [18,19]); the application of protein and 
nucleic acid biomarkers [20] and preclinical imaging techniques [21]. In human diagnostic medical 
pathology in the UK, guidance is provided for reporting pathology findings from many organ 
systems and conditions in the minimum datasets published by the Royal College of Pathology [22]. 
In contrast there is limited guidance on the reporting of pathological findings from human tissues 
in research [23] and no guidance to date covering the reporting of pathology data from animal 
tissues.  
The aim of this paper is to recommend the minimum information for publication of experimental 
pathology data (MINPEPA) (in addition to that suggested by the ARRIVE guidelines) that should be 
included when presenting pathology datasets from experimental animal studies. The guidance has 
been developed as a collaboration between expert pathologists, pathology journal editors and 
statisticians following consultation with the NC3Rs who sponsored development of the ARRIVE 
guidelines in the UK andshould provide other researchers with the ability to reproduce and 
validate novel findings. The information presented here may also serve as a primer of factors that 
can affect pathology data, and its interpretation, for researchers unfamiliar with histochemical, 
immunohistochemical (IHC), in situ hybridisation (ISH), and other routine techniques in 
morphological pathology. Critical Pathology Data to Be Reported 
1. ARRIVE guidelines 
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The ARRIVE guidelines provide clear guidance on the minimum information for reporting all 
experiments involving animals [15].  They include information that allows an experiment to be 
reproduced, and the internal and external validity of the results to be assessed, where internal 
validity is the extent to which the effects detected in an experiment are truly caused by the 
treatment and external validity is the extent to which the results can be generalised to a 
broader population. However the ARRIVE guidelines are generic, and additional pathology-
specific criteria are needed to complement them to ensure that animal-based experiments can 
be interpreted.  For example, features unique to pathology (e.g., image preparation) generally 
need detailed consideration to permit their critical analysis by readers. The critical features 
recommended for reporting pathology data are summarised in Table 1. 
2. Experimental design - managing variation and generalisability 
An experiment is designed to manage sources of variation and isolate the effect of interest 
such that there is confidence that any differences observed are due to the effect of interest 
and not arising from any other source.  This approach requires researchers to identify potential 
sources of variation in studies in advance so that they can be managed.  Most sources of 
variation are managed by standardisation (e.g., use of the same reagent lot or staining 
technique). At times it is not possible to standardise a possible source of variation (e.g., batch-
to-batch variation in staining), and in this case the study design needs to account for this (e.g., 
randomising the slides for staining between batches so that any variation is equal for both 
control and treatment groups). It is therefore important to report how sources of variation are 
managed.   
Generalisability is the ability to apply the conclusion from an experiment to a broader scenario.  
For pathology-related experiments, it is important that tissues examined are described in 
detail (including whether these were harvested and handled consistently, e.g., sampling the 
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same liver lobe in every animal) so that it is clear that the evaluation was limited to a subset of 
tissues or alternatively that the whole animal was examined systematically. Where only a 
limited number of tissues are examined to provide an illustration, this fact should be clearly 
stated. Targeted examination of limited tissue sets reflecting a particular research interest may 
help address a specific hypothesis, but will generally not allow full characterisation of an 
animal model.  Methodological standardisation, for example focusing only on a single time 
point or gender, limits variation and increases sensitivity. What is important in reporting a 
pathology dataset is to fully explain the study design and objective(s) while stating in detail the 
methodological considerations that impose possible limitations on the conclusions.  
3. Tissue harvesting and sampling at necropsy  
The methods section of research reports should give a detailed account of the techniques used 
to acquire the pathology data at necropsy including method of euthanasia, measurements 
taken (e.g., body weight), samples gathered (e.g., fluids, tissues) and whether animals were 
necropsied in a specific order. A detailed discussion of methods used to analyse all samples, 
such as clinical biochemistry and haematology for fluids or histopathologic procedures and 
morphometry techniques for tissues, should also be provided.  
Tissues for pathology evaluation are generally harvested after death. The speed with which 
samples are collected and fixed impacts cell and tissue preservation. Death does not result in 
immediate cessation of metabolism, and continuing biochemical changes can result in 
ultrastructural alterations and, ultimately, autolytic degradation of cells and tissues. These 
changes alter not only the structural appearance of tissue and cells, but also the antigenicity of 
tissue proteins [24].  All biochemical processes are heat-dependent, so the rate of change can 
be altered by the ambient temperature. Important factors to be reported are the time from 
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death until tissue harvest and initial fixation and whether the carcass was kept refrigerated 
(4oC) or held at another temperature.  
4. Fixation and post-fixation techniques 
The type of fixative (chemical or freezing); method of its application (immersion or perfusion); 
length of time in fixative; and temperature of fixation can affect both tissue morphology and 
the subsequent uses of tissue samples. Neutral buffered 10% formalin (approximately 3.7% 
formaldehyde) is the most common fixative in routine use for research studies, providing good 
preservation of morphological detail by cross-linking molecules to stabilize cell and tissue 
structures. This fixative results in a tissue cellular appearance that is well recognised by 
pathologists and most non-pathologists who perform animal-based research.  Formalin has its 
limitations, including tissue shrinkage [25] and the potential to form molecular cross-links that 
mask antigens and nucleic acids from IHC and ISH detection [26]. Paraformaldehyde is 
preferred as a fixative in some laboratories because it lacks additives (such as methanol) that 
are used to stabilise formaldehyde for long-term storage. Alcohol (ethanol or methanol) and 
acetone are sometimes used as fixatives since they coagulate tissues by removing water rather 
than cross-linking molecules. These coagulating agents generally result in poorer morphology 
and mRNA preservation but may lead to better antigen preservation relative to cross-linking 
fixatives. Freezing is often preferred for molecular pathology techniques since it does not 
damage molecular structure, but the absence of chemical preservation generally results in 
comparatively poor morphology. Clear reporting of the fixation method, including the fixative 
used, volume of tissue to fixative ratio (ideally >1:10) and the length of time spent in fixative, is 
essential when evaluating and seeking to reproduce pathology data. Specific details should be 
given regarding the fixative procedure, in particular the fixative composition—agent(s) and 
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its/their percentage strength(s)—as well as the sequence in which multiple fixatives are 
applied.  
Post-fixation techniques may be required to allow examination of specific tissue types. The 
most common example of this is the need to decalcify tissues containing bone to allow them 
to be sectioned by routine techniques following embedding in wax. Decalcification generally 
relies on the use of calcium chelators or strong acids which can significantly affect tissue 
morphology and protein and nucleic acid preservation. Exact details of post-fixation processing 
should be referenced [27].   
 
1. Tissue processing  
Tissue processing procedures generally use aqueous alcohol gradients and a transitional 
clearing agent (miscible with water and wax) to permit embedding of water-rich tissues in a 
wax or resin. Processing timings and schedules vary among laboratories, and there is little 
information on the effect that these variations have on tissue morphology. Health and safety 
concerns around historical clearing agents (e.g. benzene, toluene, chloroform and xylene) 
mean that there has been considerable interest in finding safer alternatives [28], but objective 
comparison of these newer agents (e.g. D-limonene based substitutes and 
isopropanol/mineral oil mixtures) with current practice has been limited. In practice, variations 
in chemicals or methods can produce subtle differences in tissue morphology and staining.  In 
particular, xylene-free processing has been associated with increased staining variability (C. 
Scudamore, MRC Harwell, and K Smith, Royal Veterinary College, unpublished observations). 
Therefore, tissue processing schedules, processing equipment and reagents should be 
referenced or included in supplementary data. Following processing, tissue sections are cut 
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from blocks of embedded tissue. The thickness of tissue sections should be indicated as it can 
significantly alter the appearance of cells and tissues. 
2. Conventional “tinctorial” staining.   
A variety of stains are commonly used for light microscopy with the most common being the 
“standard” combination of haematoxylin and eosin (H&E). Other more specific stains may be 
used for demonstrating structural components including carbohydrates (periodic acid–Schiff); 
connective tissue (trichrome, picrosirius red, Martius scarlet blue); fats (oil red O, Sudan black) 
and iron (Perl’s Prussian blue reaction). It is important for researchers to be aware of what 
stains actually demonstrate, the correct staining procedure, possible artefacts, the effect of 
fixation and processing on the stains, and their limitations. Stains are all dyes whose tinctorial 
characteristics can vary depending on their source and use. Even common stains like 
haematoxylin come in multiple chemical forms (often with differing stabilisers and impurities). 
The stain reference number, source, technique and randomisation method implemented 
should all be reported. Variations in staining among batches of slides stained with a particular 
dye can significantly affect the appearance of tissues and may be sufficiently extreme to 
confound interpretation [29]. One of the major sources of staining variability is the use of 
manual rather than automated procedures; if possible, manual staining should be avoided. For 
all staining techniques, precautions must be taken so that any tinctorial variability does not 
lead to an erroneous conclusion. This can be accomplished by including a mix of control and 
treated sections in each batch stained. 
3. Molecular pathology techniques (immunolabelling and in situ hybridisation) 
Immunolabelling is common in pathological analysis of human tissue and is becoming 
increasingly common for studies involving animal (especially mouse and, in diagnostic settings, 
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dog and cat) tissues, allowing detection of specific molecules. Immunolabelling includes the 
techniques of immunohistochemistry (IHC, detection via an enzyme substrate reaction) and 
immunofluorescence (IF, detection via a UV-activated fluorochrome). Many primary antibodies 
can be detected with either method, but optimal results are obtained with IF for some 
techniques and IF is often preferred for multicolour labelling of multiple antigens. IHC 
developments [30] are beginning to allow detection of the protein phosphorylation state (e.g. 
phospho-Akt, phospho-Mek, phospho-Erk) and other post-translational modifications as well 
as identifying specific alleles/single nucleotide polymorphisms (SNPs) of genes (for example 
[31]).   
To ensure reproducibility, reports of immunolabelling should define the exact details of the 
labelling procedure.  The batch of antibody should be described (supplier, monoclonal 
[including clone identification and immunoglobulin subclass] or polyclonal, and species of 
origin), including whether it has been affinity purified and whether the specificity of the 
antibody has been validated by Western blotting. Labelling conditions should be defined 
precisely (antigen retrieval methodology, antibody concentration or dilution, duration and 
temperature of incubation, detection methodology with full details of secondary and tertiary 
antisera, use of an automated or manual system).  Controls for both reagents and tissues 
should be given [32,33]. Immunofluorescence studies should include details of the detecting 
reagents and the conjugated fluorochromes, their order of application in multicolour studies, 
the fluorescence microscope, and the image capture software used.  
Ideally, each immunolabelling run should include for each primary antibody a known positive 
control (either a suitably characterised tissue or cell block composed of cells expressing the 
antigen either naturally or as a result of transfection) and a negative control.  The latter can be 
achieved by using a species- and isotype-matched primary antibody with specificity for an 
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irrelevant epitope, at the same protein concentration as the primary antibody of interest.  
Simply substituting the primary antibody with diluent (e.g., PBS) is not regarded as an 
adequate control on its own but may provide additional information on binding of secondary 
antibodies  [33,34].  The use of mouse primary antibodies on mouse tissue (“mouse on 
mouse”) requires special consideration because of the potential for artefact introduced by the 
use of anti-mouse secondary antibodies that non-specifically detect residual serum proteins 
within mouse tissue sections.  
In situ hybridisation (ISH) can detect mRNA and DNA on formalin-fixed, paraffin-embedded 
material and is often performed on an automated platform.  As for IHC, a detailed description 
of the probe characteristics (i.e., sequences, lengths), probe cocktail, tissue pre-treatment and 
probe detection method should be reported.  Appropriate controls must also be described, 
including (i) positive and negative controls for the probe set being used (ideally blocks made 
from cell lines known to express and not to express the target RNA/DNA sequence) and (ii) 
RNA/DNA preservation in the tissue of interest by means of probing a serial section for 
expression of a reference target such as Actb (Actin-beta) when detecting mRNAs as this offers 
consistent levels and patterns of expression in different cells and tissues.  Ideally, a further 
negative control should be performed on the tissue of interest, using an irrelevant probe set 
(e.g., directed against a bacterial target) or sense probes (for RNA-ISH), to detect any non-
specific labelling. When ISH for DNA is performed to look for translocations, other 
rearrangements and copy number changes, similar principles and considerations apply to 
those relevant for investigations of human tissues [35,36].  
Similar considerations apply when performing and reporting other molecular pathology 
applications used on animal tissues. Where laser capture microdissection is used, “before” and 
“after” pictures are useful to confirm that the correct cells have been sampled. Other common 
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research procedures include the use of enzyme histochemistry (to detect functional proteins) 
and lectin histochemistry (to demonstrate carbohydrates added during post-translational 
modification of proteins). In general, full details regarding reagents, methods, and control 
tissues should be given in all reports. 
4. Lesion terminology and scoring   
The pharmaceutical industry and governmental organisations have performed pathological 
analysis on laboratory animals in a systematic way for many years and have produced many 
publications giving terminology for describing and naming background pathology [37]. An 
ongoing global effort to harmonise terminology via the InHAND (International Harmonization 
of Nomenclature and Diagnostic Criteria) initiative [38] provides a comprehensive resource to 
allow pathologists and researchers to identify and interpret common pathological changes.  
Such nomenclature may not be directly translatable to descriptions of human disease entities 
for non-pathologists.  For this reason, an ontological approach to recording pathology data is 
also advocated by some parties [39].  
Lesion scoring systems depend on the nature of the finding.  Neoplastic lesions generally are 
not scored. For non-neoplastic proliferative and non-proliferative lesions, semi-quantitative 
scoring of the severity of lesions has proven a robust technique for high-throughput 
toxicological pathology analysis [40,41] that can be applied to other experimental pathology 
studies. In some instances, established scoring techniques are available in the literature; such 
as those used for colitis, experimental autoimmune encephalitis, lupus nephritis and collagen-
induced arthritis [42]. For certain organ systems, detailed classification schemes have been 
defined for animal models with the aim of relating animal scoring criteria as closely as possible 
to the WHO (World Health Organisation) equivalents for human diseases (e.g., the murine 
classification of haematopoietic neoplasms; [43,44]).  To allow comparison with other animal 
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studies and human disease, if utilised, the basis of any terminology used, the scoring system 
employed, and any modifications to published methods should be referenced or described. If a 
previously published scheme is lacking, text descriptions and/or illustrations of the criteria 
used for each score in the system must be provided.  
Semi-quantitative lesion scoring techniques result in the production of numerical data. The 
resulting lesion scores should be displayed in some form (e.g., bar graphs, incidence tables) in 
the body of the paper or supplementary data [45]. 
5. Data processing and statistical analysis  
As with all experiments, pathology data should only be discarded if there are clear technical 
reasons to do so, rather than because a result appears to be an outlier.  Ideally, reasons for 
discarding data should be defined in advance of the experiment and should be applied equally 
to control and treatment groups.  These reasons include technical concerns (e.g., tissue 
fixation / decalcification problems, inappropriate orientation of material at embedding, 
insufficient sample for analysis); inappropriate results for control samples; and pathological 
changes more likely to be related to the use of the animal strain or species.  If data are 
discarded, the reasons for doing so should be reported. 
 
Statistical analysis is used to assess whether a difference is likely a sampling effect or a real 
population difference. Common pathology data types are semi-quantitative (ordinal [e.g., 
obtained from scoring of lesions or IHC labelling]) or quantitative (continuous [e.g., 
measurements like length, weight and cell number). Selecting the appropriate statistical test is 
a function of the biological goal, the data characteristics, and the experimental design (e.g. the 
structure in the data [45]. Structure in data can arise from how experimental variation is 
managed (e.g., if multiple samples were stained in a batch and batch variation is high, then 
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samples from the same batch will be more similar) or from the design (e.g., depending on the 
experimental unit). The experimental unit (for statistical analysis) is the physical entity which 
can be assigned, at random, to a treatment. The experimental unit (whether this is an animal, 
tissue or fluid sample, or an entire litter of offspring) in pathology studies needs to be defined 
and treated as the unit in advance. If the statistics used are inappropriate, then the control of 
false positives (erroneous calls) will be poor. If in doubt regarding the appropriate tests, it is 
critical that a statistician be consulted when designing the study. For reporting purposes, it is 
necessary to report the experimental design, the experimental unit, the statistical analysis 
applied, the confidence level (α), and the calculations to ensure appropriate statistical power.  
 
6. “Blind” review 
There is much discussion regarding whether the concept of blind (also known as coded or 
masked) review is applicable to pathology data, and under what circumstances it should be 
used [46]. Blind review involves the evaluation of samples (usually stained tissue sections on 
slides) without knowledge of the experimental group from which the tissue is derived. Blinding 
to one pathology sample type (e.g., tissue sections) does not necessarily mean that the 
observer is also blind to other data gained during the course of a study.  Blind evaluation is 
considered important to avoid unintentional experimenter bias affecting the study outcome.  
It has been shown for studies involving animals or cell lines that unblinded (decoded) analysis 
is three times more likely to yield a positive result [47].  
Blinding is recommended in pathology studies where well-defined criteria for specific 
histopathological findings can be defined prior to the study [48]. In toxicological pathology 
studies, blinding a priori is not considered best practice because it may reduce sensitivity, 
particularly when changes represent part of a continuum or variation from “normal” 
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background findings, and reduces the value to be obtained from having concurrent controls 
[49,50]. Blind analysis also does not help the “inductive reasoning” process that is required to 
detect changes in novel animal models and which allows best use of an experienced 
comparative pathologist in interpreting the relevance of lesions. In practice, obvious tissue 
changes may effectively and rapidly unblind the examination. To address this unique issue in 
toxicological and experimental pathology, a common approach is to do an initial analysis of all 
tissues with full knowledge of the experimental details to ensure that all findings are detected 
and then use a subsequent blind review to confirm subtle or borderline differences in selected 
tissues [41,50,51]. The decision to evaluate slides in a blinded or non-blinded fashion or 
alternatively as non-blinded initial evaluation followed by blinded review needs to be 
considered on a case-by-case basis, and the rationale for the decision reported in the 
manuscript. 
7. Data interpretation  
Histopathology data may be produced by a subjective (descriptive or semi-quantitative) visual 
interpretation of tissue sections or by objective quantitative image analysis. Both approaches 
have considerable merit, and their relative usefulness depends on the circumstances and the 
pathophysiological questions to be answered [46,52,53]. The quality of the data and its 
interpretation will generally depend on the experience of the analyst looking at the sections. 
There are a number of examples where interpretation by inexperienced or unqualified 
researchers (‘do-it-yourself pathology’) has resulted in inaccurate interpretation of findings in 
publications [54], and there are many more undocumented examples where the lesion images 
in papers do not illustrate claims made in the text. Morphological pathology is a subjective 
skill, and there is no substitute for specific training and experience [55]. Fully trained 
experimental and comparative pathologists are usually best placed to report and interpret 
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pathology data, but there is a severe and chronic shortage of such professionals available to 
researchers [56]. While researchers should ideally collaborate with pathologists to ensure the 
accuracy of their data, where this is not possible investigators should ensure that they have 
appropriate understanding of the techniques involved and sufficient experience to identify and 
interpret lesions accurately. The quality of the pathology data is perhaps uniquely dependent 
on the skill and experience of the observer, and for this reason the person(s) responsible for 
acquiring, interpreting, and reporting these data should be clearly identified in the authors list 
or acknowledgements section. In addition, journal editors should ensure that suitably qualified 
pathologists review submitted publications where morphological data is critical to 
understanding. 
 
8. Preparation and presentation of figures 
The representation of pathology data in manuscripts and supplementary material is often 
unclear, inconsistent and/or limited to a “representative” illustrative figure. Most journals now 
offer colour publication of images (within text or supplementary material); in most instances, 
colour images are preferable. Any images presented in a figure should be representative, 
ethically prepared, and of sufficient size and quality to allow relevant features to be seen. An 
accompanying figure legend should describe specifically and clearly the essential features that 
readers including non-experts need to understand the lesion without reference to the text. A 
working knowledge of colour contrast and the effect of grayscale may enhance lesion visibility 
[57]. If good quality photomicrographs cannot be placed within the main manuscript due to 
the journal’s formatting requirements, then higher quality low- and high-power images (and 
potentially virtual slides) should be supplied in supplementary data. It is likely that the 
increasing use of digital pathology and associated computer analytical technologies will 
17 
 
facilitate image publication. Where data are summarised (e.g., in boxplot comparing scores), 
then it is critical to include information such as the numbers of animals / tissues analysed to 
allow the plots to be appropriately evaluated.  
Unethical image presentation and manipulation is a significant factor in scientific fraud [58]. 
The minimum degree of image manipulation should be used to ensure that a clear, 
representative and reproducible image that represents the original data is shown in the final 
publication [59]. Ethical manipulations may include global corrections of white balance, 
uneven background and colour balance; conversion from colour to grayscale or among colour 
modes (e.g., RGB to CMYK); and image sharpening. Many journals actively encourage 
submission of RGB images as these will allow the best representation of the captured image 
when viewed on screen, leaving conversion into the more restricted CMYK colour space in the 
hands of their printers. Cropping and straightening an image may be required to present an 
image correctly but should not be used to create a false impression of the lesion or avoid 
showing flaws. Resizing by upscaling will increase the number of pixels, but will create data 
that wasn’t originally present. Certain file types can result in “lossy compression” (loss of 
image data) as occurs with JPEG formats; TIFF files with LZW compression are “lossless” yet 
may reduce file sizes significantly. Certain manipulations may be unavoidable when producing 
an image to journal specifications for publication but should definitely be avoided when 
making measurements from images. A copy of the original image prior to manipulation should 
be retained in the pathologist’s records along with the software log (for example, from a given 
version of Adobe Photoshop or Image J) recording the manipulations used to create the 
published image. A statement regarding the adjustments made should be included in the 
methods or in the figure legend (for example, “Images were individually adjusted in Adobe 
Photoshop CS5, including white balance and contrast adjustment”). Manipulation of focal 
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areas of an image [58], the use of some software filters, and cloning tools are examples of 
unacceptable image manipulations [59]. 
Care should be taken when specifying the magnification of images. Mentioning the original 
magnification provided by the microscope when the image was taken does not take into 
account the effect of splitters or camera attributes, or any further image manipulation or 
resizing [59], and generally should be avoided. As it is usually not possible to predict the final 
size of the image when it is published, it is best to include a scale bar in the original image that 
will be scaled as the image is manipulated.  
The principles for documenting clinical and laboratory images in publications (the CLIP 
principles, [60]) are endorsed by the Journal of Pathology and provide clear guidance that 
covers the points discussed above. The summary principles are given in Table 2. 
 
Conclusion 
Morphological pathology data are extremely valuable in defining the tissue responses in animal 
models and allowing for translation of animal-derived data to predict biological responses in 
human and animal disease conditions. The approaches used in traditional pathology are well 
established, but the numerous reagents and methods mean that there is not a universal standard 
for even the most “routine” techniques. Analysis of tissue sections mounted on glass slides or as 
virtual slide images is still largely dependent on a human observer, and the quality of the results 
and their interpretation is therefore uniquely dependent on that individual’s training and 
experience as a morphologist.  Here we extend the ARRIVE guidelines by suggesting a 
recommended 12-point checklist of critical pathology data to be reported in publications. This 
framework for reporting pathology data will maximise the likelihood that pathology data derived 
from experiments in animal models can be reproduced and understood. 
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Table 1: Minimum set of critical pathology data to be reported in addition to the ARRIVE 
guidelines 
  Recommendations 
1 ARRIVE • Generic requirements for all in vivo experiments 
2 Experimental design • Detail the experimental design  
• Describe efforts to minimise variation and bias (e.g., 
standardisation of reagents, randomisation of groups) 
• Provide details of tissues examined, numbers of animals and time 
points 
• Controls (negative and positive) 
3 Tissue harvesting  • Sample list (tissues and fluids) 
• Tests performed (clinical chemistry, haematology, histopathology, 
morphometry, etc.) 
• Interval between death and specimen collection / initial tissue 
fixation 
• Temperature at which the body was held until specimen collection 
/ initial tissue fixation 
4 Fixation 
 
• Fixative type(s): chemical (cross-linking vs. coagulating), physical 
(e.g., freezing) 
• Fixative composition: single agent vs. multi-agent (e.g., 
Karnovsky’s) 
• Tissue: Fixative volume ratio 
• Number of fixative changes (and the interval between each 
exchange) 
• Method of fixation: immersion vs. perfusion 
• Length of storage in fixative 
• Temperature of fixation 
• Use of post-fixation (e.g. for decalcification) 
5 Processing technique • Reagents for tissue dehydration and clearing 
• Sequence of dehydration and clearing steps 
• Lengths of dehydration and clearing steps 
• Temperatures of dehydration and clearing steps 
6 Conventional/Tinctorial 
stain  
 
• Reagents (including vendor) 
• Procedure (technical details and/or literature citation) 
7 Molecular techniques 
 
 
 
 
 
 
 
 
Immunohistochemistry (IHC)  
• Antibody properties: class/subclass, nature (monoclonal vs. 
polyclonal), host species, clone, lot, vendor  
• Antibody manufacturing: affinity purification, conjugate labelling 
• IHC procedure: antigen retrieval methodology, blocking 
procedures, antibody concentration, incubation times and 
temperatures, detection methodology, counterstain, process 
(manual vs. automated), special considerations (e.g., mouse-on-
mouse kits) 
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• Control materials: reagents (specific vs. spurious) and tissues 
(positive vs. negative) 
 In situ hybridisation/cytogenetic (ISH) 
• Probe properties: type (DNA, RNA, peptide nucleic acid (PNA)), 
length (oligomer vs. longer sequence), and sequence (including 
database accession no.), and if applicable lot and vendor  
• Probe manufacturing: conjugate labelling 
• ISH procedure: probe sequences and concentrations, cocktail 
recipes, incubation times and temperatures, detection 
methodology, counterstain, process (manual vs. automated) 
• Control materials: reagents (specific vs. spurious) and tissues 
(positive vs. negative) 
8 Lesion terminology and 
scoring system used 
 
• Terminology: definitions, ontology, and/or literature citation 
• Scoring system: detailed criteria (text and ideally visual depictions) 
and/or literature citation 
• Digital imaging algorithms  
9 Data processing and 
statistical analysis 
• Experimental unit 
• Reasons for data exclusion and how many samples were affected 
• Statistical tests used 
10 Blind (coded) review • Endpoint(s) subject to blind analysis 
• Timing of blind analysis (a priori vs. post hoc) 
• Rationale for approach taken (blind review from the beginning or 
blind or non-blind initial evaluation followed by blind review) 
11 Data interpretation • Qualifications and/ or training of person acquiring, interpreting, 
and reporting pathology data, to be included in author list or 
acknowledgements section 
12 Preparation and 
presentation of figures 
• Nature of lesions depicted (representative vs. exceptional) 
• Global image manipulations: white and colour balance, conversion 
(e.g. colour to grayscale), image sharpening 
• Scale bar 
 
Table 2. The CLIP Principles for documenting pathology images in publications (adapted from 
Lang et al 2012 [60])* 
The following data regarding pathology images should be reported: 
1. The subject of the image 
2. Details of the acquisition of the image 
3. Details of the selection of the image 
4. Details of any modifications to the image 
5. Important details of the image itself 
6. Details of the analysis or interpretation  
7. Implications of the image 
*It is recommended that potential authors consult the full publication by Lang et al 2012 [60] for 
further details. 
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